News
VCYT
44.68
-3.73%
-1.73
Veracyte: Diagnostics With Favorable Economics
Seeking Alpha · 2d ago
Weekly Report: what happened at VCYT last week (0803-0807)?
Weekly Report · 3d ago
Veracyte: Core Growth Funds Prosigna And TrueMRD
Seeking Alpha · 3d ago
Veracyte Price Target Cut to $54.00/Share From $66.00 by Piper Sandler
Dow Jones · 08/04 14:52
Veracyte Is Maintained at Overweight by Piper Sandler
Dow Jones · 08/04 14:52
Piper Sandler Maintains Overweight on Veracyte, Lowers Price Target to $54
Benzinga · 08/04 14:41
Stephens Keeps Their Buy Rating on Veracyte (VCYT)
TipRanks · 08/04 13:45
Piper Sandler Sticks to Its Buy Rating for Veracyte (VCYT)
TipRanks · 08/04 13:26
Veracyte Price Target Cut to $55.00/Share From $68.00 by Stephens & Co.
Dow Jones · 08/04 13:17
Veracyte Is Maintained at Overweight by Stephens & Co.
Dow Jones · 08/04 13:17
Stephens & Co. Maintains Overweight on Veracyte, Lowers Price Target to $55
Benzinga · 08/04 13:07
Veracyte Price Target Cut to $44.00/Share From $47.00 by Morgan Stanley
Dow Jones · 08/04 12:52
Veracyte Is Maintained at Underweight by Morgan Stanley
Dow Jones · 08/04 12:52
Morgan Stanley Maintains Underweight on Veracyte, Lowers Price Target to $44
Benzinga · 08/04 12:42
Veracyte price target lowered to $44 from $47 at Morgan Stanley
TipRanks · 08/04 12:05
Veracyte price target lowered to $55 from $68 at Stephens
TipRanks · 08/04 11:17
Veracyte price target lowered to $54 from $66 at Piper Sandler
TipRanks · 08/04 10:56
Veracyte Price Target Cut to $50.00/Share From $60.00 by Canaccord Genuity
Dow Jones · 08/03 21:39
Veracyte Is Maintained at Hold by Canaccord Genuity
Dow Jones · 08/03 21:39
Canaccord Genuity Maintains Hold on Veracyte, Lowers Price Target to $50
Benzinga · 08/03 21:29
More
Webull provides a variety of real-time VCYT stock news. You can receive the latest news about Veracyte through multiple platforms. This information may help you make smarter investment decisions.
About VCYT
Veracyte, Inc. is a global diagnostics company. It enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA laboratories in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.